Cyclophosphamide combined with bone marrow mesenchymal stromal cells protects against bleomycin-induced lung fibrosis in mice

Annals of Clinical and Laboratory Science

Volumn 45, Issue 3, 2015, Pages 292-300

  Xu, Jiabo ^a   Li, Li ^b   Xiong, Jianfei ^a   Zheng, Ying ^a   Ye, Qing ^a   Li, Yanqin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Bone marrow mesenchymal stromal cells (BM MSCs); Cyclophosphamide (CP); Pulmonary fibrosis (PF); Red fluorescence protein; Stromal cell derived factor (SDF 1)

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; HYDROXYPROLINE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; RED FLUORESCENT PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; COLLAGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; BONE MARROW CELL; BONE MARROW MESENCHYMAL STROMAL CELL; BRONCHUS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRIEND MURINE LEUKEMIA VIRUS; FRIEND VIRUS B TYPE; IN VITRO STUDY; LUNG; LUNG ALVEOLUS; LUNG FIBROSIS; LUNG PARENCHYMA; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; WILD TYPE; ANIMAL; BIOASSAY; CELL DIFFERENTIATION; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PULMONARY FIBROSIS;

FRIEND MURINE LEUKEMIA VIRUS; MUS;

ANIMALS; BIOLOGICAL ASSAY; BLEOMYCIN; CELL DIFFERENTIATION; CHEMOKINE CXCL12; COLLAGEN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GENE EXPRESSION REGULATION; HYDROXYPROLINE; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; PLATELET-DERIVED GROWTH FACTOR; PULMONARY FIBROSIS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 84934280050     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Meltzer E, Noble P. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008; 3:8.
2. Biswas R, Bunderson-Schelvan M, and Holian A. Potential Role of the Inflammasome-Derived Inflammatory Cytokines in Pulmonary Fibrosis. Pulmonary Medicine 2011; 2011:8-14.
3. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-664.
4. Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, Charbord P, Domenech J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25:1737-1745.
5. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG. Mesenchymal stem cell engraftment in lung is enhanced in response to BLM esposure and ameliorates its fibrotic effect. Proc Natl Acad Sci USA 2003; 100:8407-8411.
6. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33:145-152.
7. Drouet M, Mourcin F, Grenier N, Delaunay C, Mayol JF, Lataillade JJ, Peinnequin A, Hérodin F. Mesenchymal stem cells rescue CD34+cells fromradiation-induced apoptosis and sustain hematopoietic re-constitution after coculture and cografting in lethally irradiated baboons: is autologous stem cell therapy in nuclear accident set-tings hype or reality. Bone Marrow Transplant 2005; 35:1201-1209.
8. Fiorucci E, Lucantoni G, Paone G, Zotti M, Li BE, Serpilli M, Regimenti P, Cammarella I, Puglisi G, Schmid G. Colchicine, cyclophosphamide and prednisone in the treatment of mildmoderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. Eur Rev Med Pharmacol Sci 2008; 12:105-111.
9. Pereira CA, Malheiros T, Coletta EM, Ferreira RG, Rubin AS, Otta JS, Rocha NS. Survival in idiopathic pulmonary fibrosiscytotoxic agents compared to corticosteroids. Respir Med 2006; 100:340-347.
10. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir and Crit Care Med 2000;161:646-664.
11. Wang X, Yang CK. Stromal cell derived factor-1 and its receptor CXCR4 in cancer research progress. Medicine Review 2007; 13:296-297.
12. Vaquero J, Otero L, Bonilla C, Aguayo C, Rico MA, Rodriguez A, Zurita M. Cell therapy with bone marrow stromal cells after intracerebral hemorrhage: impact of platelet-rich plasma scaffolds. Cytotherapy 2013;15:33-43.
13. Ochoa R, Bejarano PA, Glück S, Montero AJ. Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep 2012; 6:413.
14. Assi K, Patterson S, Dedhar S, Owen D, Levings M, Salh B. Role of epithelial integrin-linked kinase in promoting intestinal inflammation: effects on CCL2, fibronectin and the T cell repertoire. BMC Immunol 2011; 12:42.
15. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122:286-289.
16. Shi XF, Fu JX, Liang JY. Research on homing characteristics of bone marrow mesenchymal stem cells in vivo. Jiangsu Journal of Medicine 2004; 30:284-286.
17. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proceedings of the American Thoracic Society 2006; 3:357-363.
18. Wang ZL. Advances in understanding of idiopathic pulmonary fibrosis. Chinese Medical Journal 2009; 122:844-857.
19. Sun LY, Han MZ. Chemotactic effect of stromal cell derived factor on bone marrow mesenchymal stem cells. World J Gastroenterol 2008; 16:992-997.
20. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004; 113:243-252.
21. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114:438-446.
22. Lama VN, Phan SH. The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc 2006; 3:373-376.
23. Zhao F, Zhang YF, Liu YG, Zhou JJ, Li ZK, Wu CG, Qi HW. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on BLM-induced lung injury in rats. J Transplant Proc 2008; 40:1700-1705.